Jeffrey M. Smith

Jeffrey M. Smith

Auto-generated profile, based on publicly available information

Jeffrey M. Smith

Colonial Foundation Diagnostics Centre, New Medicines and Diagnostics Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
APAngela Pizzolla
Angela Pizzolla
TNThi H. O. Nguyen
Thi H. O. Nguyen
JSJeffrey M. Smith
Jeffrey M. Smith
ABAndrew G. Brooks
Andrew G. Brooks
KKKatherine Kedzierska
Katherine Kedzierska
LWLinda M Wakim
Linda M Wakim
Nasal epithelial tissue of the upper respiratory tract is the first site of contact by inhaled pathogens such as influenza virus. We show that this region is key to limiting viral spread to the lower respiratory tract and associated disease pathology. Immunization of the upper respiratory tract leads to the formation of local tissue-resident memory CD8+ T cells (Trm cells). Unlike Trm cells in the lung, these cells develop independently of local cognate antigen recognition and transforming growth factor–β signaling and persist with minimal decay, representing a long-term protective population. Repertoire characterization revealed unexpected differences between lung and nasal tissue Trm cells, the composition of which was shaped by the developmental need for lung, but not nasal, Trm cells to recognize antigen within their local tissue. We show that influenza-specific Trm cells in the nasal epithelia can block the transmission of influenza virus from the upper respiratory tract to the lung and, in doing so, prevent the development of severe pulmonary disease. Our findings reveal the protective capacity and longevity of upper respiratory tract Trm cells and highlight the potential of targeting these cells to augment protective responses induced to respiratory viral vaccines.


21 April 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ASAngus T. Stock
Angus T. Stock
JSJeffrey M. Smith
Jeffrey M. Smith
FCFrancis R. Carbone
Francis R. Carbone
Infection induces the expression of inflammatory chemokines that recruit immune cells to the site of inflammation. Whereas tissues such as the intestine and skin express unique chemokines during homeostasis, whether different tissues express distinct chemokine profiles during inflammation remains unclear. With this in mind, we performed a comprehensive screen of the chemokines expressed by two tissues (skin and sensory ganglia) infected with a common viral pathogen (herpes simplex virus type 1). After infection, the skin and ganglia showed marked differences in their expression of the family of Cxcr2 chemokine ligands. Specifically, Cxcl1/2/3, which in turn controlled neutrophil recruitment, was up-regulated in the skin but absent from the ganglia. Within the ganglia, Cxcl2 expression and subsequent neutrophil recruitment was inhibited by type I interferon (IFN). Using a combination of bone marrow chimeras and intracellular chemokine staining, we show that type I IFN acted by directly suppressing Cxcl2 expression by monocytes, abrogating their ability to recruit neutrophils to the ganglia. Overall, our findings describe a novel role for IFN in the direct, and selective, inhibition of Cxcr2 chemokine ligands, which results in the inhibition of neutrophil recruitment to neuronal tissue.

23 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GIGiuseppe Infusini
Giuseppe Infusini
JSJeffrey M. Smith
Jeffrey M. Smith
HYHe Yuan
He Yuan
APAngela Pizzolla
Angela Pizzolla
WNWy Ching Ng
Wy Ching Ng
LWLinda M Wakim
Linda M Wakim
Respiratory dendritic cells (DC) play a pivotal role in the initiation of adaptive immune responses to influenza virus. To do this, respiratory DCs must ferry viral antigen from the lung to the draining lymph node without becoming infected and perishing en route. We show that respiratory DCs up-regulate the expression of the antiviral molecule, interferon-induced transmembrane protein 3 (IFITM3) in response to influenza virus infection, in a manner dependent on type I interferon signaling and the transcription factors IRF7 and IRF3. Failure of respiratory DCs to up-regulate IFITM3 following influenza virus infection resulted in impaired trafficking to the draining LN and consequently in impaired priming of an influenza-specific CD8+ T cell response. The impaired trafficking of IFITM3-deficient DC correlated with an increased susceptibility of these DC to influenza virus infection. This work shows that the expression of IFITM3 protects respiratory DCs from influenza virus infection, permitting migration from lung to LN and optimal priming of a virus specific T-cell response.

27 April 2020 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
CECyril Engmann
Cyril Engmann
JFJessica A. Fleming
Jessica A. Fleming
SKSadaf Khan
Sadaf Khan
BIBruce Innis
Bruce Innis
JSJeffrey M. Smith
Jeffrey M. Smith
AMAjoke Sobanjo-Ter Meulen
Ajoke Sobanjo-Ter Meulen
This state-of-the art manuscript highlights our current understanding of maternal immunization—the practice of vaccinating pregnant women to confer protection on them as well as on their young infants, and thereby reduce vaccine-preventable morbidity and mortality. Advances in our understanding of the immunologic processes that undergird a normal pregnancy, studies from vaccines currently available and recommended for pregnant women, and vaccines for administration in special situations are beginning to build the case for safe scale-up of maternal immunization. In addition to well-known diseases, new diseases are emerging which pose threats. Several new vaccines are currently under development and increasingly include pregnant women. In this manuscript, targeted at clinicians, vaccinologists, scientists, public health practitioners, and policymakers, we also outline key considerations around maternal immunization introduction and delivery, discuss noninfectious horizons for maternal immunization, and provide a framework for the clinician faced with immunizing a pregnant woman.

3 November 2016 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
APAngela Pizzolla
Angela Pizzolla
JSJeffery M. Smith
Jeffery M. Smith
ABAndrew G. Brooks
Andrew G. Brooks
PRPatrick Reading
Patrick Reading
Influenza remains a major global health issue and the effectiveness of current vaccines and antiviral drugs is limited by the continual evolution of influenza viruses. Therefore, identifying novel prophylactic or therapeutic treatments that induce appropriate innate immune responses to protect against influenza infection would represent an important advance in efforts to limit the impact of influenza. Cellular pattern recognition receptors (PRRs) recognize conserved structures expressed by pathogens to trigger intracellular signaling cascades, promoting expression of proinflammatory molecules and innate immunity. Therefore, a number of approaches have been developed to target specific PRRs in an effort to stimulate innate immunity and reduce disease in a variety of settings, including during influenza infections. Herein, we discuss progress in immunomodulation strategies designed to target cell-associated PRRs of the innate immune system, thereby, modifying innate responses to IAV infection and/or augmenting immune responses to influenza vaccines.